Masimo Corp. (MASI) recently reported that its new customer, Nassau University Medical Center (NUMC), has completed its system-wide conversion to Masimo SET pulse oximetry technology. The conversion allows clinicians to monitor NUMC patients non-invasively using the latest pulse oximetry technology. This in turn provides real time data for vital parameters that aid clinicians in faster and accurate patient treatments.
Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), oxyhemoglobin (SpO2), methemoglobin (SpMet), acoustic respiration rate (RRa), pulse rate (PR), and perfusion index (PI), etc.
Masimo SET pulse oximetry eliminates the need to draw blood and wait for results. This helps physicians to immediately detect and treat potentially fatal conditions.
Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems consisting of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. Hypoxemia, low blood-oxygen levels, can cause brain damage and death. Hyperoxemia, high-blood oxygen levels, can permanently damage eyes and cause blindness.
Masimo is a leader in the pulse oximetry monitoring equipment market. The company’s closest competitors are Haemonetics Corp. (HAE) and Becton, Dickinson and Co. (BDX).
Presently, we have a ‘Neutral’ recommendation on Masimo Corp.
Read the full analyst report on “MASI”
Read the full analyst report on “HAE”
Read the full analyst report on “BDX”
Zacks Investment Research
